Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Sep;38(9):1681-1688.
doi: 10.3174/ajnr.A5316. Epub 2017 Jun 29.

Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study)

Affiliations
Randomized Controlled Trial

Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study)

K R Maravilla et al. AJNR Am J Neuroradiol. 2017 Sep.

Abstract

Background and purpose: Effective management of patients with brain tumors depends on accurate detection and characterization of lesions. This study aimed to demonstrate the noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors.

Materials and methods: This multicenter, double-blind, randomized, controlled intraindividual, crossover, noninferiority study included 279 patients. Both contrast agents (dose = 0.1 mmol/kg of body weight) were assessed with 2 identical MRIs at a time interval of 2-14 days. The primary end point was overall lesion visualization and characterization, scored independently by 3 off-site readers on a 4-point scale, ranging from "poor" to "excellent." Secondary end points were qualitative assessments (lesion border delineation, internal morphology, degree of contrast enhancement, diagnostic confidence), quantitative measurements (signal intensity), and safety (adverse events). All qualitative assessments were also performed on-site.

Results: For all 3 readers, images of most patients (>90%) were scored good or excellent for overall lesion visualization and characterization with either contrast agent; and the noninferiority of gadoterate meglumine versus gadobutrol was statistically demonstrated. No significant differences were observed between the 2 contrast agents regarding qualitative end points despite quantitative mean lesion percentage enhancement being higher with gadobutrol (P < .001). Diagnostic confidence was high/excellent for all readers in >81% of the patients with both contrast agents. Similar percentages of patients with adverse events related to the contrast agents were observed with gadoterate meglumine (7.8%) and gadobutrol (7.3%), mainly injection site pain.

Conclusions: The noninferiority of gadoterate meglumine versus gadobutrol for overall visualization and characterization of primary brain tumors was demonstrated.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Patient disposition with numbers of patients enrolled (n = 279) and randomized (n = 274) to undergo 2 identical MR imaging examinations with gadoterate meglumine followed by gadobutrol (arm 1) or with gadobutrol followed by gadoterate meglumine (arm 2). A total of 268 patients received the first contrast agent injection, and 249 patients completed the study with the 2 examinations performed.
Fig 2.
Fig 2.
Rate of patients with overall lesion visualization and characterization scored good/excellent or poor/fair. The bar graph shows the rate of patients with overall lesion visualization and characterization scored good/excellent or poor/fair according to each contrast agent and each off-site reader (n = 234 patients for all readers).
Fig 3.
Fig 3.
A 46-year-old woman with glioblastoma. T1 spin-echo images (1.5T) after administration of 0.1 mmol/kg of gadoterate meglumine (A) and gadobutrol (B) show an approximate 65-mm lesion. The time between the 2 MR imaging examinations was 7 days. Lesion visualization and characterization were scored as excellent by all 3 blinded readers. The enhancing rim of the lesion is clearly seen on both examinations.
Fig 4.
Fig 4.
A 74-year-old man with a high-grade glioma. T1 spin-echo images (1.5T) after administration of 0.1 mmol/kg of gadoterate meglumine (A) and gadobutrol (B) show an approximate 30-mm mass. The time between the 2 MR imaging examinations was 8 days. Lesion visualization and characterization were scored as excellent by all 3 blinded readers. The mass is clearly seen on both examinations and shows no difference in contrast enhancement.
Fig 5.
Fig 5.
Classification in preference subgroups for lesion border delineation (A), lesion internal morphology (B), and degree of contrast enhancement (C). The bar graphs show the rate of patients classified in preference subgroups for lesion border delineation (A), lesion internal morphology (B), and degree of contrast enhancement (C), according to each off-site reader (n = 234 patients for all readers; n = 231 patients for reader 1; n = 233 patients for reader 2; n = 232 patients for reader 3), with P > .1 for the 3 end points for all readers (Wilcoxon signed rank test).

References

    1. Rohrer M, Bauer H, Mintorovitch J, et al. . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715–24 10.1097/01.rli.0000184756.66360.d3 - DOI - PubMed
    1. Anzalone N, Scarabino T, Venturi C, et al. . Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol 2013;82:139–45 10.1016/j.ejrad.2011.07.005 - DOI - PubMed
    1. Maravilla KR, Smith MP, Vymazal J, et al. . Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study). AJNR Am J Neuroradiol 2015;36:14–23 10.3174/ajnr.A4154 - DOI - PMC - PubMed
    1. Katakami N, Inaba Y, Sugata S, et al. . Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases. Invest Radiol 2011;46:411–18 10.1097/RLI.0b013e3182145a6c - DOI - PubMed
    1. Oudkerk M, Sijens PE, Van Beek EJ, et al. . Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995;30:75–78 10.1097/00004424-199502000-00002 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources